Heart Metrics Solutions is a healthcare technology startup positioning itself as a leader in non-invasive heart disease screening. The deck highlights a three-pronged product approach: AI-powered ECG interpretation, continuous wearable monitoring, and seamless EHR integration. The company claims significant early traction, reporting over 10,000 customers across the US, Canada, and Europe, alongside $5 million in revenue for the past year. Despite these strong top-line figures, the deck lacks a specific funding ask, detailed unit economics, or a competitive landscape analysis. The financial pr…
Key takeaways
- The company claims a 99% accuracy rate for its screening technology on slide 5.
- Heart Metrics Solutions reports $5M+ in revenue over the past year with a 50% quarter-over-quarter growth rate (slide 5).
- The product suite includes AI-powered ECG analysis and continuous wearable monitoring (slide 3).
- The deck identifies a $500 billion annual cost for heart disease treatment as the primary market driver (slide 6).
- The team is led by a board-certified cardiologist, a CTO with healthcare software experience, and a Ph.D. in Biomedical Engineering (slide 7).
- Financial projections on slide 8 show revenue growing from $4.3M in 2023 to $7M in 2027, though 2025 shows a projected revenue decrease to $3.5M.
- The company claims to have an FDA-cleared device and a 4.85-star rating (slide 5).
- The deck omits a specific dollar amount for the 'Seed Series' funding ask and does not list existing investors.
Heart Metrics Solutions Pitch Deck Teardown
Heart Metrics Solutions (HMS) positions itself at the intersection of artificial intelligence and cardiovascular health. This teardown examines their 9-slide presentation, which outlines a seed-stage company that claims to already have significant market traction and regulatory clearance.
Slide 1: Title Slide
The cover slide introduces the company name, Heart Metrics Solutions, and the tagline "Revolutionizing Heart Disease Screening." It explicitly labels the presentation as a "Seed Series Pitch Deck." The visual design uses a dark blue theme with a stylized 3D heart model, establishing a professional, medical-technology aesthetic immediately.
Slide 2: Introduction, Mission, and Vision
This slide defines HMS as a "healthcare tech startup dedicated to transforming the landscape of heart disease screening." The mission statement focuses on "early detection and prevention... through advanced and non-invasive screening technology." The vision is to become a "global leader" in the space. While standard, these statements clearly define the company’s scope as a preventative diagnostic tool rather than a treatment provider.
Slide 3: Innovative Features
The product slide breaks down the offering into three pillars: AI-Powered ECG Analysis , Continuous Wearable Monitoring , and Seamless EHR Integration . The text claims the AI algorithms interpret ECG data "accurately" for "early detection." The mention of EHR integration is a vital value proposition for healthcare providers, as it reduces administrative friction and allows for a "holistic view of patients' heart health."
Slide 4: Advancing Heart Health Science
This slide focuses on the R&D and validation side of the business. It lists four areas of focus: Research Collaborations with cardiologists, expansion into other areas like hypertension and arrhythmia detection, continuous software updates, and "rigorous clinical validation studies." This slide is intended to build credibility by showing that the technology is rooted in scientific evidence rather than just software development.
Slide 5: The Future of Heart Health Screening (Traction)
This is the most data-dense slide in the deck. It lists several key metrics: 10,000+ customers in the US, Canada, and Europe; $5M+ revenue in the past year; a 50% quarter-over-quarter growth rate ; and 20+ partnerships with providers and insurers. It also claims 99% accuracy and notes an FDA-cleared device . These figures are exceptionally high for a seed-stage company, suggesting the company may be further along in its commercialization than the "Seed" label typically implies.
Slide 6: Market Opportunity
HMS quantifies the problem by citing "over 17 million deaths per year" and "$500 billion costs annually" for heart disease treatment. The slide identifies three target markets: Low-Income Communities (affordability), Aging Population (increased need), and Remote and Underserved Areas (cloud-based access). By framing the solution as "accessible and affordable," the company targets the high-volume, lower-cost screening market.
Slide 7: Meet the Team
The team slide features three key roles. Dr. Emily Parker (CMO) brings 15+ years of clinical experience. Johnathan Lee (CTO) provides the software engineering background. Dr. Sarah Johnson (Lead Data Scientist) brings the academic and research weight with a Ph.D. in Biomedical Engineering. The team appears well-balanced between clinical expertise, technical execution, and data science.
Slide 8: Financial Projections
The "Path Ahead" slide provides a bar chart of projected revenue and expenses from 2023 to 2027. The numbers are presented in millions (though the units are not explicitly labeled on the Y-axis, the context of the $5M revenue claim on slide 5 suggests these are millions). Curiously, the chart shows revenue at 4.3 in 2023, dropping to 2.5 in 2024 and 3.5 in 2025, before spiking to 4.5 in 2026 and 7 in 2027. The deck also promises a "4x return" for seed investors within 5 years. The dip in revenue in the middle years is unusual for a pitch deck and is not explained in the text.
Slide 9: Contact Information
The final slide provides a generic contact email (invest@heartmetricssolutions.com), a placeholder phone number, and a website link. It invites potential investors to "get in touch and explore further discussions."
What Works in This Deck
Strong Traction Metrics: Claiming $5M in revenue and 10,000 customers provides immediate validation that there is a market for the product. · Regulatory Clarity: The mention of an FDA-cleared device on slide 5 removes a major hurdle for healthcare investors who are often wary of regulatory risks. · Clear Product Pillars: Slide 3 does a good job of explaining that this isn't just a wearable, but an integrated AI and data platform.
What Is Missing from This Deck
The Ask: The deck is labeled "Seed Series," but nowhere does it state how much capital the company is looking to raise or how that capital will be deployed. · Competitive Landscape: There is no mention of existing players like AliveCor, iRhythm, or even Apple/Samsung, who all have heart-monitoring capabilities. · Unit Economics: While total revenue is mentioned, there is no information on the cost of goods sold (COGS), customer acquisition cost (CAC), or the business model (subscription vs. device sale). · Financial Logic: The revenue dip in the 2024-2025 projections on slide 8 is a major red flag that requires an explanation. Typically, decks show a consistent upward trajectory; a planned dip usually implies a major pivot or a transition in business models that isn't detailed here.
What a Founder Should Copy
The "Traction at a Glance" Slide: Using a map with clear icons for revenue, accuracy, and customer count (as seen on slide 5) is an effective way to communicate scale quickly. · Role-Specific Team Bios: The team slide (slide 7) focuses on the specific credentials that matter for this industry—clinical experience for the CMO and biomedical engineering for the data scientist. · Market Problem Framing: Slide 6 effectively connects the human cost (deaths) to the economic cost ($500B), making the market opportunity feel both urgent and massive.
Frequently asked questions
- What is the core technology behind Heart Metrics Solutions?
- According to slide 3, the core technology consists of AI-powered ECG analysis using state-of-the-art algorithms to interpret data for early detection of heart conditions. This is supplemented by continuous wearable monitoring for real-time data collection and integration with Electronic Health Records (EHR) to provide healthcare providers with a holistic view of patient health.
- What level of traction has the company achieved?
- Slide 5 states that the company has over 10,000 customers across the US, Canada, and Europe. They report a 95% customer satisfaction rate and have generated over $5 million in revenue in the past year. Additionally, they claim to have established over 20 partnerships with healthcare providers and insurance companies.
- Who are the key members of the leadership team?
- The team featured on slide 7 includes Dr. Emily Parker (Chief Medical Officer), a board-certified cardiologist with 15+ years of experience; Johnathan Lee (Chief Technology Officer), a software engineer focused on data analytics; and Dr. Sarah Johnson (Lead Data Scientist), who holds a Ph.D. in Biomedical Engineering specializing in cardiovascular health.
- What are the projected financial outcomes for investors?
- Slide 8 suggests that seed series investors can expect a 4x return on investment (ROI) within a 5-year period. The revenue is projected to reach $7 million by 2027, although the chart indicates a period of higher expenses relative to revenue in 2024 and a revenue dip in 2025 before scaling up again.
- Does the deck mention regulatory compliance?
- Yes, slide 5 includes a badge stating the company has an 'FDA-cleared device.' This is a critical milestone for med-tech startups, as it indicates the product has met the necessary regulatory standards for sale and use in the United States healthcare market.
